MedPath

Fluconazole

Generic Name
Fluconazole
Brand Names
Diflucan
Drug Type
Small Molecule
Chemical Formula
C13H12F2N6O
CAS Number
86386-73-4
Unique Ingredient Identifier
8VZV102JFY
Background

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.

Indication

Fluconazole can be administered in the treatment of the following fungal infections:

1) Vaginal yeast infections caused by Candida

2) Systemic Candida infections

3) Both esophageal and oropharyngeal candidiasis

4) Cryptococcal meningitis

5) UTI (urinary tract infection) by Candida

6) Peritonitis (inflammation of the peritoneum) caused by Candida

A note on fungal infection prophylaxis

Patients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy and/or radiation therapy may be predisposed to candida infections, and may receive fluconazole as prophylactic therapy.

A note on laboratory testing

Obtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment. It is permissible to start therapy before the results are available, however, adjusting the therapy once laboratory results confirm the causative organism may be necessary.

Associated Conditions
Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis

Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor

Phase 4
Recruiting
Conditions
Pityriasis Versicolor
Interventions
First Posted Date
2025-04-10
Last Posted Date
2025-04-10
Lead Sponsor
Khyber Teaching Hospital
Target Recruit Count
106
Registration Number
NCT06922344
Locations
🇵🇰

Khyber Teaching Hospital, Peshawar, KPK, Pakistan

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

Phase 1
Recruiting
Conditions
RSV Infection
Drug Drug Interaction (DDI)
Interventions
First Posted Date
2025-02-26
Last Posted Date
2025-02-26
Lead Sponsor
Enanta Pharmaceuticals, Inc
Target Recruit Count
48
Registration Number
NCT06847464
Locations
🇺🇸

ICON, plc, San Antonio, Texas, United States

Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride

Phase 1
Completed
Conditions
Interaction Drug Food
Interventions
First Posted Date
2025-02-12
Last Posted Date
2025-02-14
Lead Sponsor
Ahon Pharmaceutical Co., Ltd.
Target Recruit Count
68
Registration Number
NCT06822166
Locations
🇨🇳

The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province), Jinan, Shandong, China

Introduction of Mycotic Prophylaxis At Cystectomy Trial.

Phase 4
Recruiting
Conditions
Cystectomy
Interventions
Drug: Isotonic saline solution
First Posted Date
2025-01-13
Last Posted Date
2025-01-13
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
484
Registration Number
NCT06770530
Locations
🇩🇰

Department of Urology, Rigshospitalet, Copenhagen, Denmark

Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis

Phase 4
Recruiting
Conditions
Cystectomy
Bladder Cancer Requiring Cystectomy
Postoperative Infections
Antibiotic Prophylaxis
Ileal Conduit
Interventions
First Posted Date
2024-11-29
Last Posted Date
2025-01-09
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
248
Registration Number
NCT06709196
Locations
🇩🇰

Department of Urology, Aalborg University Hospital, Aalborg, Denmark

🇩🇰

Department of Urology, Aarhus University Hospital, Aarhus, Denmark

🇩🇰

Department of Urology, Rigshospitalet, Copenhagen, Denmark

and more 2 locations

A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-04-03
Last Posted Date
2025-04-27
Lead Sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Target Recruit Count
50
Registration Number
NCT06345794
Locations
🇺🇸

ICON San Antonio Clinical Research Unit, San Antonio, Texas, United States

Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease

Phase 3
Recruiting
Conditions
Inflammatory Bowel Diseases
Crohn's Disease
Interventions
Drug: Placebo
Biological: IL-23 Therapy
First Posted Date
2024-02-23
Last Posted Date
2024-10-29
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
120
Registration Number
NCT06274554
Locations
🇺🇸

Weill Cornell Medicine, New York, New York, United States

A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults

First Posted Date
2023-12-15
Last Posted Date
2024-06-20
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
60
Registration Number
NCT06173596
Locations
🇬🇧

Research Site, Ruddington, United Kingdom

Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.

Not Applicable
Recruiting
Conditions
Vaginal Yeast Infections
Vulvovaginal Candidiasis
Interventions
Drug: JUVIA zinc containing vaginal gel treatment
First Posted Date
2023-06-08
Last Posted Date
2023-06-13
Lead Sponsor
FEMPHARMA Kft.
Target Recruit Count
76
Registration Number
NCT05895162
Locations
🇭🇺

Dr. Secret Private Clinic, Debrecen, HB, Hungary

Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor

Phase 1
Completed
Conditions
Tinea Versicolor
Interventions
First Posted Date
2023-05-17
Last Posted Date
2023-05-17
Lead Sponsor
Combined Military Hospital Abbottabad
Target Recruit Count
164
Registration Number
NCT05862714
Locations
🇵🇰

CMH Abbottabad, Abbottābād, Khyber Pakhtunkhwa, Pakistan

© Copyright 2025. All Rights Reserved by MedPath